AML-MDS 001

Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS (AML-MDS 001)

What's the purpose of the trial?

The purpose of this study is to understand the safety and estimate the efficacy of combining anti-CD3 x anti-CD33 bispecific antibody (CD33Bi) armed fresh peripheral blood mononuclear cells (CD33Bi FPBMC) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) where they still have detectable disease ("MRD+") after some treatment.

Trial status

Accepting patients

Phase
Phase 1
Enrollment
23
Last Updated

For Healthcare Professionals Only

This site is intended for healthcare professionals in the US. Patients and care partners can explore and connect with MDS clinical trials through our patient portal.

View Patient Portal

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • CD33 FPBMC

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

CD33 FPBMC + Hypomethylating Agent with or without Venetoclax

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.